Edition:
United Kingdom

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

25.48USD
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
$25.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
76,062
52-wk High
$38.35
52-wk Low
$21.27

Latest Key Developments (Source: Significant Developments)

Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA.THERAVANCE BIOPHARMA INC - ‍FILED SUPPLEMENTAL NEW DRUG APPLICATION WITH U.S. FDA FOR USE OF TRELEGY ELLIPTA​.  Full Article

Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Theravance Biopharma Inc -:Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease.Theravance Biopharma Inc - ‍NDA is supported by companies' Phase 3 program for revefenacin​.  Full Article

Theravance Biopharma posts Q3 loss of $1.27 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Theravance Biopharma Inc :Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update.Q3 revenue $4.3 million versus i/b/e/s view $4.6 million.Cash, cash equivalents and marketable securities, excluding restricted cash, totaled $434.4 million as of september 30, 2017​.Qtrly basic and diluted net loss per share $1.27‍​.  Full Article

Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Mylan Nv :Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting.Theravance Biopharma Inc - ‍remain on track to submit an NDA for Revefenacin Q4 of 2017​.Theravance Biopharma Inc - ‍results demonstrated statistically significant and clinically meaningful improvements for revefenacin over placebo ​.Theravance Biopharma Inc - ‍both doses of revefenacin had comparable rates of adverse events to placebo​.  Full Article

Theravance Biopharma Q2 revenue $5.5 million
Monday, 8 Aug 2016 

Theravance Biopharma Inc : Q2 revenue $5.5 million . Theravance Biopharma Inc reports second quarter 2016 financial results and provides business update . Q2 revenue view $12.7 million -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-1.05 -- Thomson Reuters I/B/E/S .Qtrly loss per share $1.06.  Full Article

BRIEF-Theravance Biopharma Reports Qtrly Loss Per Share $1.22

* THERAVANCE BIOPHARMA, INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE